PDS Biotechnology Corp Enters New Agreement, Terminates Old
Ticker: PDSB · Form: 8-K · Filed: May 2, 2025 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | May 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, debt-obligation, equity-sale
TL;DR
PDS Biotech inked a new deal, ditched an old one, took on debt, and sold stock on April 30th.
AI Summary
On April 30, 2025, PDS Biotechnology Corporation entered into a material definitive agreement and simultaneously terminated a prior agreement. The company also incurred a direct financial obligation and engaged in unregistered sales of equity securities. The filing details these events and includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions, including new financial obligations and equity sales, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, suggesting significant corporate changes that carry inherent risks.
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- April 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 26-4231384 (tax_id) — I.R.S. Employer Identification No.
- 303A College Road East, Princeton, NJ 08540 (address) — Principal Executive Offices
- 800-208-3343 (phone_number) — Registrant's phone number
FAQ
What was the nature of the material definitive agreement entered into by PDS Biotechnology Corporation on April 30, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
Which prior agreement was terminated by PDS Biotechnology Corporation on April 30, 2025?
The filing states that a material definitive agreement was terminated, but the specific name or details of the terminated agreement are not included in the provided text.
What type of direct financial obligation did PDS Biotechnology Corporation create?
The filing mentions the creation of a direct financial obligation, but the specific nature or amount of this obligation is not detailed in the excerpt.
Were there any unregistered sales of equity securities by PDS Biotechnology Corporation?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information, indicating such sales occurred.
What is the principal business of PDS Biotechnology Corporation?
PDS Biotechnology Corporation is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 2, 2025 regarding PDS Biotechnology Corp (PDSB).